0001140361-23-033190.txt : 20230705
0001140361-23-033190.hdr.sgml : 20230705
20230705210033
ACCESSION NUMBER: 0001140361-23-033190
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230630
FILED AS OF DATE: 20230705
DATE AS OF CHANGE: 20230705
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Grossman Adam S
CENTRAL INDEX KEY: 0001542517
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36728
FILM NUMBER: 231071763
MAIL ADDRESS:
STREET 1: 65 COMMERCE WAY
CITY: HACKENSACK
STATE: NJ
ZIP: 07601
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC.
CENTRAL INDEX KEY: 0001368514
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 562590442
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O ADMA BIOLOGICS, INC.
STREET 2: 465 STATE ROUTE 17
CITY: RAMSEY
STATE: NJ
ZIP: 07446
BUSINESS PHONE: (201) 478-5552
MAIL ADDRESS:
STREET 1: C/O ADMA BIOLOGICS, INC.
STREET 2: 465 STATE ROUTE 17
CITY: RAMSEY
STATE: NJ
ZIP: 07446
FORMER COMPANY:
FORMER CONFORMED NAME: R&R ACQUISITION VI, INC
DATE OF NAME CHANGE: 20060707
4
1
form4.xml
X0407
4
2023-06-30
0001368514
ADMA BIOLOGICS, INC.
ADMA
0001542517
Grossman Adam S
C/O ADMA BIOLOGICS, INC.
465 STATE ROUTE 17
RAMSEY
NJ
07446
true
true
President and CEO
false
Common Stock
2023-06-30
4
F
0
20051
3.69
D
2523085
D
Common Stock
1143426
I
See Footnote
Common Stock
580957
I
See Footnote
Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 340,313 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;
(continued from footnote 1) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;
(continued from footnote 2) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,254,736 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.
These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden.
/s/ Adam S. Grossman, by Brian Lenz as Attorney-in-fact
2023-07-05